The overall goal of this project is to develop a rapid, highly sensitive assay to detect the presence of anthrax. To achieve this goal we have developed a novel, proprietary technology with several advantages over currently used PCR-based methods. This technology, called SPIATM [single primer isothermal amplification] can amplify nucleic acids in an isothermal, homogeneous manner with expected sensitivity and specificity equal to and perhaps greater than PCR. Furthermore, the method does NOT suffer from the cross-contamination problems of PCR. In this Phase I proposal we expect to validate these claims and develop a test suitable for widespread use. Therefore we will a) optimize SPIATM and demonstrate sensitivity and specificity of SPIATM control sequences, b) demonstrate use of SPIATM using B. anthracis sequences, and c) validate SPIATM using B. subtills spores. In Phase II we will integrate this technology into detection device(s) with expanded field studies to evaluate sensitivity, specificity, etc.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AI052674-01
Application #
6552051
Study Section
Special Emphasis Panel (ZRG1-SSS-K (12))
Program Officer
Swain, Amy L
Project Start
2002-07-01
Project End
2002-12-31
Budget Start
2002-07-01
Budget End
2002-12-31
Support Year
1
Fiscal Year
2002
Total Cost
$100,000
Indirect Cost
Name
Nugen Technologies, Inc.
Department
Type
DUNS #
089441146
City
San Carlos
State
CA
Country
United States
Zip Code
94070